China Digest: BSBE, National Pharmaceutical to buy MXB; Fosun backs Mingxun

BSBE has teamed up with National Pharmaceutical Investment to acquire MXB for $371 million. In a separate development, new material company Mingxun Hi-Tech Material Joint-Stock has raised ‘tens of millions of US dollars’ in a new funding round from Fosun, Addor Capital and Cowin Capital.

BSBE, National Pharmaceutical to buy MXB for $371m

SZ-listed in-vitro diagnostics (IVD) service provider Beijing Strong Biotechnologies Inc (BSBE) has tied up with state-owned China National Pharmaceutical Investment to pick up an aggregate of 95.55 per cent stake in MXB Biotechnologies for 2.6 billion yuan ($371 million), according to a company filing with Shenzhen Stock Exchange.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter